Abstract: Ester derivatives of low molecular weight heparin are disclosed. These derivatives exhibit improved Anti-Xa activity in relation to global anticlotting activity.

Abstract: Regression of established malignant tumors in rats, mice and hamsters is achieved with a combination of the heparin fragment hexuronyl hexosaminoglycan sulfate (HHS) together with a steroid such as hydrocortisone. HHS is clinically useful for its antineoplastic, inhibiting effects in tumor systems in rats, mice and hamsters.

Abstract: The present invention relates to a process for obtaining low molecular weight heparins endowed with pharmacological and therapeutic properties of outstanding interest, starting from normal heparin.The said process is characterized in that it comprises the following steps:(a) acidification of normal heparin to obtain heparinic acid,(b) depolymerization of said heparinic acid by heating in autoclave in the presence of peroxides, to obtain a low molecular weight heparamine,(c) sulphation of said heparamine to obtain the corresponding low molecular weight heparin.A further object of the invention is the low molecular weight heparins, or LMW heparins, so obtained, and their utilization in the field of therapeutics.